STAT+ reports that China’s tightened rules have disrupted investigator-initiated clinical trials, turning what had been a faster, lower-cost pathway into a “trickle” after deaths and new government requirements upended trial plans. The story centers on families and foundations seeking to run investigator-initiated trials (IIT) for rare diseases, including the Hope for Rare Foundation. Clinicians and advocates describe the policy shift as a reversal of the loosened framework that previously enabled trials to start without central regulator sign-off. That speed also contributed to interest from multinational developers—some of whom either moved trials to China or pushed for similar regulatory models at home. For biopharma decision-makers, the immediate implication is operational uncertainty for rare-disease and other IIT-driven programs reliant on the prior cadence of start approvals. Trial sponsors will likely need to rework timelines and regulatory pathways as China’s review expectations evolve.